Home
overview

SMi is proud to present their 7th annual Pharmaceutical Parallel Trade Conference . Parallel trade 2013 aims to provide you with the latest developments from industry experts across a range of sectors. Parallel trade has shown to be a rapidly expanding – stay on top of the latest regulations and strategies of both traders and those who try who can take advantage of open trading.

The growth of parallel trade can often divide opinions. Free movements of goods across the EU has meant better access to cheaper drugs to many patients. It has however opened up an increasingly bigger problem facing healthcare professionals in counterfeit drugs, something that can often lead to huge losses in revenues for pharmaceutical companies, and thus effect future investment in R&D.

Parallel trade 2013 aims to show you both sides of the argument between trading of medicines – taking industry experts in patient safety, IP law, counterfeiting, and parallel traders.

  • Hear from industry experts from both sides of the fence – how does this affect your company?
  • Learn about market access and pricing strategies – how do traders affect drug access with big pharma
  • Parallel Trade 2013 is one of the only true events on this subject, develop your understanding in how traders affect patients
  • Listen to industry experts on issues with counterfeiting of drugs and patient safety, what happens when open access is taken advantage of?
  • Big pharma speakers will present on the effects of trading on R&D pipelines and intellectual property issues, when does patient access to drugs at a fair price begin to hinder future drugs being developed?
  • Pricing
  • Market access
  • Health technology assessment
  • Supply chain management
  • Intellectual property
  • Health economics
  • Anti-counterfeiting
  • Intellectual property
  • Packaging
  • Director
  • Area Head
  • CSO
  • Vice President
  • Market Access
  • Manager

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Eric Noehrenberg

Eric Noehrenberg , Director, Public Affairs for Market Access, Shire Pharmaceuticals

9:10 Impact of parallel trade on patients

Eric Noehrenberg

Eric Noehrenberg , Director, Public Affairs for Market Access, Shire Pharmaceuticals

  • Do patients benefit from parallel trade
  • Safety concerns
  • Quality issues
  • Public health impact
  • 9:50 GS1 Standards: Foundational to the EU supply chain

    Janice Kite

    Janice Kite, Traceability Director Healthcare, GS1 Global Office

  • It’s not just EU!
  • GS1 Standards for Healthcare: Process and Technical Standards
  • The move to implementation
  • How GS1 Standards can assist in the fight against counterfeit, improving patient safety and in compliance to the Directive for Falsified Medicines directive

     

  • 10:30 Morning Coffee

    11:00 Creating a supply chain model for demand management and controlling service provision by country / affiliate

    Nosh Lentin

    Nosh Lentin, Mangaing Director, Operations & Supply Mngt. Ltd.

  • Segmenting customer demand at country level
  • Obtaining data to monitor weekly demand
  • Setting gates for manging level of demand
  • Execute and monitoring performance
  • 11:40 Taking patient safety to a next level: The stakeholder driven European Medicines Verification System ESM

    Heinz Kobelt

    Heinz Kobelt, Director European Affairs, European Association of Euro-Pharmaceutical Companies

  • Patient safety in parallel distribution today
  • Next step: ESM-stakeholder approach for implementing the falsified medicines directive
  • ESM - Technical features and governance model
  • Connecting in the real world: Integrating manufacturers, wholesalers, pharmacies and parallel distributors
  • The EMS as a cost effective way to ensure a high level of patient safety
  • 12:20 Networking Lunch

    13:40 Life after the Falsified Medicines Directive - opportunities and threats

    Mike Isles

    Mike Isles, Executive Director, European Alliance for Access to Safe Medicines

  • We live in the 21st centuary - let's embrace that
  • Where will the counterfeiter peddle his wares now?
  • How can we ensure that patients are protected and truly benefit from the FMD
  • 14:20 Parallel trade and pharmaceutical company dynamics

    Doina Ionescu

    Doina Ionescu, Managing Director, Merck

  • Facts and figures
  • Local global company implications
  • Local environment issues
  • 15:00 Afternoon Tea

    15:30 Impact and response of pharmaceutical industry to parallel trade

    Fabrizio Gianfrate

    Fabrizio Gianfrate, Professor of Health Economics, University of Ferrara

  • Impact on pharmaceutical industry R&D investments
  • Strategies of pharmaceutical industries to contrast PT
  • Potential EU and local countries regulatory scenarios
  • 16:20 Managing parallel trade – practical guidance for manufacturers

    Janice Haigh

    Janice Haigh, Practice Leader, Market Access, Europe, Quintiles Consulting

  • What is the impact of parallel trade on pharmaceutical manufacturers?
  • What are the available strategies for managing parallel trade?
  • What are the legal and practical challenges?
  • How should we address these?
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Eric Noehrenberg

    Eric Noehrenberg , Director, Public Affairs for Market Access, Shire Pharmaceuticals

    9:10 Parallel Import in Poland - the third legitimate market player

    Tomasz Dzitko

    Tomasz Dzitko, Founder and CEO , Delfarma

  • The economies of parallel import
  • Initiatives of parallel importers in the context of falsified medicines directive
  • Optimisation of the supply chain
  • A way forward
  • 9:50 Parallel trade from a competition law perspective – an update

    Axel Schulz

    Axel Schulz, Partner, White & Case LLP

  • Update on relevant case-law
  • Restructuring of the greek market
  • New interest by the European Commission
  • 10:30 Morning Coffee

    11:00 Intellectual Property Update

    Christopher Stothers

    Christopher Stothers, Partner, Arnold and Porter

  • Using the Specific Mechanism to prevent parallel imports from “new” Member States
  • Using Border Controls to stop parallel imports
  • Impact of developments in other fields of parallel trade
  • 11:40 Pharmaceutical innovation and parallel trade

    Anna Rita Bennato

    Anna Rita Bennato, Post Doc Research Fellow, University Of East Anglia

  • Parallel trade in the pharmaceutical sector
  • Interaction between government regulation policies and parallel trade
  • Focus on policy in the pharmaceutical sector
  • Patent holders decisions under a regime of parallel trade
  • 12:20 Networking Lunch

    13:50 The impact of the Falsified Medicines Directive on parallel imports

    Peter Bogaert

    Peter Bogaert, Partner, Food & Drug Law, Covington & Burling Belgium

  • Safety features and their impact
  • Specific aspects of repackaging
  • Regulatory controls
  • 14:30 Effects of parallel trade on affordable access to medicines

    Dermot Glynn

    Dermot Glynn, Chairman, Europe Economics

  • The eurocrisis and parallel trade
  • How to ensure safe supplies of medicines for hard-hit countries
  • Optimal pricing strategies within the EU
  • 15:10 Afternoon Tea

    15:40 Why parallel trade exists? - A traders point of view

    Antonio Mendonca Alves

    Antonio Mendonca Alves, CEO, MD Pharma SA

  • Benefits to consumers
  • general access to medicines within the EU
  • Benefits of a single EU market to wholesaling strategies
  • patient and government savings in the importing contries
  • Profits and tax revinues in exporting countries
  • 16:20 PANEL DISCUSSION - The future of parallel trade

    Eric Noehrenberg

    Eric Noehrenberg , Director, Public Affairs for Market Access, Shire Pharmaceuticals

    Tomasz Dzitko

    Tomasz Dzitko, Founder and CEO , Delfarma

    Peter Bogaert

    Peter Bogaert, Partner, Food & Drug Law, Covington & Burling Belgium

    Jim Thomson

    Jim Thomson, Chair, European Alliance for Access to Safe Medicines

    17:00 Chairman’s Closing Remarks and Close of Day Two

    +

    FEATURED SPEAKERS

    Doina Ionescu

    Doina Ionescu

    Managing Director, Merck
    Eric Noehrenberg

    Eric Noehrenberg

    Director, Public Affairs for Market Access, Shire Pharmaceuticals
    Tomasz Dzitko

    Tomasz Dzitko

    Founder and CEO , Delfarma

    Anna Rita Bennato

    Post Doc Research Fellow, University Of East Anglia
    Anna Rita Bennato

    Antonio Mendonca Alves

    CEO, MD Pharma SA
    Antonio Mendonca Alves

    Axel Schulz

    Partner, White & Case LLP
    Axel Schulz

    Christopher Stothers

    Partner, Arnold and Porter
    Christopher Stothers

    Dermot Glynn

    Chairman, Europe Economics
    Dermot Glynn

    Doina Ionescu

    Managing Director, Merck
    Doina Ionescu

    Eric Noehrenberg

    Director, Public Affairs for Market Access, Shire Pharmaceuticals
    Eric Noehrenberg

    Fabrizio Gianfrate

    Professor of Health Economics, University of Ferrara
    Fabrizio Gianfrate

    Heinz Kobelt

    Director European Affairs, European Association of Euro-Pharmaceutical Companies
    Heinz Kobelt

    Janice Haigh

    Practice Leader, Market Access, Europe, Quintiles Consulting
    Janice Haigh

    Janice Kite

    Traceability Director Healthcare, GS1 Global Office
    Janice Kite

    Jim Thomson

    Chair, European Alliance for Access to Safe Medicines
    Jim Thomson

    Mike Isles

    Executive Director, European Alliance for Access to Safe Medicines
    Mike Isles

    Nosh Lentin

    Mangaing Director, Operations & Supply Mngt. Ltd.
    Nosh Lentin

    Peter Bogaert

    Partner, Food & Drug Law, Covington & Burling Belgium
    Peter Bogaert

    Tomasz Dzitko

    Founder and CEO , Delfarma
    Tomasz Dzitko

    Workshops

    Parallel Trade in Life Sciences
    Workshop

    Parallel Trade in Life Sciences

    Copthorne Tara Hotel
    5th February 2013
    London, United Kingdom

    Parallel Trade Management Strategies
    Workshop

    Parallel Trade Management Strategies

    Copthorne Tara Hotel
    5th February 2013
    London, United Kingdom

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.